rabeprazole

(redirected from Aciphex Sprinkle)
Also found in: Dictionary.

rabeprazole

 [rah-bep´rah-zōl]
an inhibitor of stomach hydrochloric acid secretion administered orally as the sodium salt in treatment of gastroesophageal reflux disease and similar conditions marked by excessive acid.

rabeprazole

/ra·bep·ra·zole/ (rah-bep´rah-zōl) a proton pump inhibitor used as the sodium salt to inhibit gastric acid secretion in the treatment of gastroesophageal reflux disease and conditions marked by excessive secretion of gastric acid.

rabeprazole

a proton pump inhibitor.
indications Rabeprazole is used to treat gastroesophageal reflux disease (GERD), severe erosive esophagitis, poorly responsive systemic GERD, pathological hypersecretory conditions such as Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas, and active duodenal ulcers.
contraindication Known hypersensitivity to this drug prohibits its use.
adverse effects Life-threatening effects are proteinuria, hematuria, pancytopenia, thrombocytopenia, neutropenia, and leukocytosis. Other adverse effects include abdominal swelling, anorexia, irritable colon, esophageal candidiasis, epistaxis, urticaria, alopecia, hypoglycemia, increased hepatic enzymes, weight gain, tinnitus, angina, tachycardia, bradycardia, palpitations, peripheral edema, urinary tract infection, increased creatinine, testicular pain, glycosuria, and fever. Common side effects include headache, dizziness, asthenia, diarrhea, abdominal pain, vomiting, nausea, constipation, flatulence, acid regurgitation, upper respiratory infections, cough, rash, and back pain.

rabeprazole

Aciphex® GI disease A proton pump inhibitor used to manage for heartburn, duodenal ulcers, gastric ulcers, GERD, hypersecretory conditions–eg, Zollinger-Ellison syndrome. See GERD.
References in periodicals archive ?
On March 26, 2013, the US Food and Drug Administration approved ACIPHEX Sprinkle Delayed-Release Capsules 5mg and 10mg for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks.
Eisai president and CEO Lonnel Coats said: Eisai is committed to making Aciphex Sprinkle available to appropriate patients as part of our human health care (hhc) corporate mission of keeping patients medical needs at the forefront of all that we do.
Aciphex Sprinkle Delayed-Release Capsules 5mg and 10mg will be obtainable in US drugstores only with a prescription.
Eisai, a Japan-based pharmaceutical company, has introduced Aciphex Sprinkle Delayed-Release Capsules 5mg and 10mg to be administered to eligible patients by prescription in the United States, it was reported yesterday.
Eisai (TYO: 4523), a Japan-based pharmaceutical company, has received approval from the US FDA for ACIPHEX Sprinkle as a 12-week gastroesophageal reflux disease therapy for use in children between one to eleven years of age.